Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bilobalide** is a natural sesquiterpene trilactone isolated from the leaves of *Ginkgo biloba*. It is a primary terpenoid component of Ginkgo extracts and possesses extensive pharmacological actions. Bilobalide exhibits **neuroprotective**, **antioxidant**, **anti-inflammatory**, **anti-ischemic**, and **cardiovascular protective** activities. Mechanistically, bilobalide acts as a **negative allosteric modulator of GABA-A and GABA-A-rho receptors**, potentially influencing cognitive and memory functions, with selectivity for certain receptor subunits. It also acts as a glycine receptor antagonist and an enzyme modulator (induces CYP3A1, CYP1A2, and activates constitutive androstane receptor). Additional mechanisms include inhibition of neuronal apoptosis, protection against hypoxia-induced cellular damage, upregulation of mitochondrial respiratory chain proteins, and promotion of amyloid-beta degrading enzymes in astrocytes. Bilobalide has demonstrated protection against neuronal injury in models of Alzheimer's disease and vascular dementia[1][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bilobalide.